Target intelligence / Profile preview

Caseinolytic peptidase B protein homolog (CLPB)

Target
CLPB
Molecular classification
Enzyme, AAA+ ATPase (ATPases Associated with diverse cellular Activities), Disaggregase, Mitochondrial protein
01

Overview

CLPB (SKD3) is a mitochondrial AAA+ ATPase disaggregase found in the intermembrane space of human mitochondria. It has a distinctive N-terminal ankyrin repeat domain, unlike other canonical AAA+ proteins, which is essential for its higher-order oligomeric assembly and disaggregase activity. The protein uses conserved pore-loops in its ATPase ring to grip and translocate substrate polypeptides, driven by ATP hydrolysis. Its activity regulates mitochondrial proteostasis by solubilizing aggregated mitochondrial proteins; proteolytic activation by PARL protease enhances its function. Mutations in CLPB cause severe metabolic and hematological disorders, such as 3-methylglutaconic aciduria type VII and congenital neutropenia, highlighting its critical roles in human biology and disease etiology[1][2][3][4].

Other names
SKD3Mitochondrial AAA+ disaggregaseHuman ClpBCaseinolytic peptidase B protein homologSkd3
02

Mechanism of action

For potential drugs, the expected mechanism would include: - Modulating ATPase activity (activation or inhibition) - Influencing ankyrin domain or rhomboid protease PARL-mediated cleavage (regulation of disaggregase activity) - Enhancing substrate solubilization/disaggregation (therapeutic activation)

03

Biological functions

Protein disaggregation and solubilizationMaintenance of mitochondrial proteostasisReactivation of aggregated or misfolded proteins in mitochondriaRegulation of mitochondrial structure (e.g., cristae remodeling)Interacts with proteins involved in apoptosis (e.g., Hax1)
04

Disease associations

Neurological disorders (mutations cause neurological symptoms)Severe congenital neutropenia (SCN)3-methylglutaconic aciduria type VII (MGCA7)Premature ovarian insufficiency
05

Safety considerations

Potential off-target effects when modulating critical mitochondrial proteostasisRisk of triggering or exacerbating mitochondrial dysfunctionUnknown long-term risks due to its central role in cell survival and apoptosis pathways
06

Biomarkers

CLPB mutation status for diagnosis or prognosis of MGCA7 and SCNLevels of aggregated mitochondrial substrate proteins (e.g., Hax1, OPA1) in patient mitochondrial samples

Beyond the preview

Go deeper on Caseinolytic peptidase B protein homolog (CLPB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caseinolytic peptidase B protein homolog (CLPB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call